News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thousands Of Prostate Patients Denied Astellas Pharma Inc. (ALPMY) Drug That Can Extend Life In Watchdog U-Turn



1/28/2014 8:00:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Thousands of men with advanced prostate cancer could be denied a new drug after a U-turn by the NHS rationing body.

Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES